Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Current guidelines and prioritizing treatment of hepatitis C virus in HIV-infected patients

Current guidelines and prioritizing treatment of hepatitis C virus in HIV-infected patients Downloaded from http://journals.lww.com/co-hivandaids by BhDMf5ePHKbH4TTImqenVA5KvPVPZ0P5BEgU+IUTEfzO/GUWifn2IfwcEVVH9SSn on 06/03/2020 REVIEW URRENT Current guidelines and prioritizing treatment of PINION hepatitis C virus in HIV-infected patients a b c,d,e Eoin R. Feeney , Raymond T. Chung , and Yazdan Yazdanpanah Purpose of review Coinfection with hepatitis C virus (HCV) and HIV is a significant public health problem worldwide. The broad spectrum antivirals interferon-alpha (IFN) and ribavirin (RBV) have lower sustained virologic response rates in HIV–HCV coinfection compared with HCV monoinfection, with significant associated toxicities and prolonged treatment courses. The recent availability of direct acting antivirals (DAA) has transformed the treatment of HCV, with the opportunity of cure available for most patients with much more tolerable regimens. These regimens are now being studied in HIV–HCV coinfection. Recent findings DAA-based regimens for HIV–HCV coinfection have shown excellent efficacy, with cure rates similar to HCV monoinfection. Either in combination with IFN and RBV, or in ‘IFN-free’ regimens, cure rates of over 90% are the goal for all HIV–HCV-infected individuals. Data are excellent in genotype 1 infection, but further data on genotype 2–6 are required. These regimens have been shown to be cost-effective in HCV monoinfection, and are likely to be cost-effective in HIV–HCV coinfection. Nonetheless they http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Current Opinion in HIV & AIDS Wolters Kluwer Health

Current guidelines and prioritizing treatment of hepatitis C virus in HIV-infected patients

Download PDF
7 pages

Loading next page...
 
/lp/wolters-kluwer-health/current-guidelines-and-prioritizing-treatment-of-hepatitis-c-virus-in-OzTMlxvHUU

References

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

Publisher
Wolters Kluwer Health
ISSN
1746-630X
eISSN
1746-6318
DOI
10.1097/COH.0000000000000178
Publisher site
See Article on Publisher Site

Abstract

Downloaded from http://journals.lww.com/co-hivandaids by BhDMf5ePHKbH4TTImqenVA5KvPVPZ0P5BEgU+IUTEfzO/GUWifn2IfwcEVVH9SSn on 06/03/2020 REVIEW URRENT Current guidelines and prioritizing treatment of PINION hepatitis C virus in HIV-infected patients a b c,d,e Eoin R. Feeney , Raymond T. Chung , and Yazdan Yazdanpanah Purpose of review Coinfection with hepatitis C virus (HCV) and HIV is a significant public health problem worldwide. The broad spectrum antivirals interferon-alpha (IFN) and ribavirin (RBV) have lower sustained virologic response rates in HIV–HCV coinfection compared with HCV monoinfection, with significant associated toxicities and prolonged treatment courses. The recent availability of direct acting antivirals (DAA) has transformed the treatment of HCV, with the opportunity of cure available for most patients with much more tolerable regimens. These regimens are now being studied in HIV–HCV coinfection. Recent findings DAA-based regimens for HIV–HCV coinfection have shown excellent efficacy, with cure rates similar to HCV monoinfection. Either in combination with IFN and RBV, or in ‘IFN-free’ regimens, cure rates of over 90% are the goal for all HIV–HCV-infected individuals. Data are excellent in genotype 1 infection, but further data on genotype 2–6 are required. These regimens have been shown to be cost-effective in HCV monoinfection, and are likely to be cost-effective in HIV–HCV coinfection. Nonetheless they

Journal

Current Opinion in HIV & AIDS – Wolters Kluwer Health

Published: Sep 1, 2015

There are no references for this article.